Title |
Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
|
---|---|
Published in |
International Journal of Chronic Obstructive Pulmonary Disease, December 2013
|
DOI | 10.2147/copd.s52557 |
Pubmed ID | |
Authors |
Vamsi Bollu, Frank R Ernst, John Karafilidis, Krithika Rajagopalan, Scott B Robinson, Sidney S Braman |
Abstract |
Inpatient admissions for chronic obstructive pulmonary disease (COPD) represent a significant economic burden, accounting for over half of direct medical costs. Reducing 30-day readmissions could save health care resources while improving patient care. Recently, the Patient Protection and Affordable Care Act authorized reduced Medicare payments to hospitals with excess readmissions for acute myocardial infarction, heart failure, and pneumonia. Starting in October 2014, hospitals will also be penalized for excess COPD readmissions. This retrospective database study investigated whether use of arformoterol, a nebulized long-acting beta agonist, during an inpatient admission, had different 30-day all-cause readmission rates compared with treatment using nebulized short-acting beta agonists (SABAs, albuterol, or levalbuterol). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 63 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 19% |
Student > Master | 9 | 14% |
Other | 8 | 13% |
Student > Bachelor | 7 | 11% |
Student > Doctoral Student | 4 | 6% |
Other | 13 | 21% |
Unknown | 10 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 41% |
Nursing and Health Professions | 9 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
Economics, Econometrics and Finance | 3 | 5% |
Agricultural and Biological Sciences | 2 | 3% |
Other | 7 | 11% |
Unknown | 11 | 17% |